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Abstract
Background: High-grade non-muscle invasive bladder cancer (NMIBC) has a high risk of recurrence and progression
to muscle-invasive forms, which seems to be largely related to the presence of tumorigenic stem-like cell populations
that are refractory to conventional therapies. Here, we evaluated the therapeutic potential of Natural Killer
(NK) cell-based adoptive immunotherapy against chemoresistant bladder cancer stem-like cells (CSCs) in a pre-clinical
relevant model, using NK cells from healthy donors and NMIBC patients.
Methods: Cytokine-activated NK cells from healthy donors and from high-grade NMIBC patients were phenotypically
characterized and assayed in vitro against stem-like and bulk differentiated bladder cancer cells. Stem-like cells were
isolated from two bladder cancer cell lines using the sphere-forming assay. The in vivo therapeutic efficacy was
evaluated in mice bearing a CSC-induced orthotopic bladder cancer. Animals were treated by intravesical instillation of
interleukin-activated NK cells. Tumor response was evaluated longitudinally by non-invasive bioluminescence imaging.
Results: NK cells from healthy donors upon activation with IL-2 and IL-15 kills indiscriminately both stem-like and
differentiated tumor cells via stress ligand recognition. In addition to cell killing, NK cells shifted CSCs towards a more
differentiated phenotype, rendering them more susceptible to cisplatin, highlighting the benefits of a possible
combined therapy. On the contrary, NK cells from NMIBC patients displayed a low density on NK cytotoxicity receptors,
adhesion molecules and a more immature phenotype, losing their ability to kill and drive differentiation of CSCs. The
local administration, via the transurethral route, of activated NK cells from healthy donors provides an efficient tumor
infiltration and a subsequent robust tumoricidal activity against bladder cancer with high selective cytolytic activity
against CSCs, leading to a dramatic reduction in tumor burden from 80 % to complete remission.
Conclusion: Although pre-clinical, our results strongly suggest that an immunotherapeutic strategy using allogeneic
activated NK cells from healthy donors is effective and should be exploited as a complementary therapeutic strategy in
high-risk NMIBC patients to prevent tumor recurrence and progression.
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Background
Bladder cancer (BC) is the most common malignancy of
the urinary tract, and one of the leading causes of cancer
death in Western countries [1, 2]. Although the majority
of the newly diagnosed cases are non-muscle-invasive
tumors (NMIBC), up to 80 % recur and a significant part
progresses to therapy refractory muscle-invasive forms
(MIBC) [3, 4].
A recent report from our group demonstrated that
MIBC harbor distinct cell subsets reflecting molecular
features of stem-like cells endowed with enhanced che-
moresistance and tumor initiating ability [5]. In addition
to the inefficacy of conventional chemotherapy towards
bladder cancer stem-like cells (CSCs), we also showed
that a short-term exposure to cisplatin induced a pheno-
typic cell state transition to an adaptive stem-like pheno-
type, providing evidence for the tumor plasticity and
spontaneous switching between cell states when subjected
to stressful conditions such as chemotherapy [5]. Evidence
from other groups supports our findings, reinforcing the
hypothesis of a driver role of those cells in the frequent re-
lapses of BC, as well as a fuel to the progression towards
invasive forms [6, 7]. Therefore, the development of thera-
peutic strategies aimed to target cancer stemness is essen-
tial to prevent tumor relapse and progression, and
represents an important challenge in BC management.
Natural Killer (NK) cells are important players of the
innate immune system with a strong cytolytic activity
against virus-infected or neoplastic cells [8] without
prior immune sensitization, which make them appealing
therapeutic effectors against cancer [9]. These cells se-
crete inflammatory cytokines and chemokines that sub-
sequently shape the innate and adaptive immune
response by promoting differentiation, activation and re-
cruitment of accessory immune cells to the tumor site
[10, 11]. The biological activity of NK cells is regulated
by the dynamic balance between activating and inhibi-
tory signals provided by the interaction with the target
cells, and by soluble factors released in the tumor micro-
environment, which together dictate their efficacy [12].
NK cells express a variety of activating receptors, includ-
ing the NK group 2 member D (NKG2D), the DNAX
accessory molecule-1 (DNAM-1), and the natural cyto-
toxicity receptors (NCRs: NKp30, NKp44, and NKp46),
that provide activating signals upon binding to stress-
induced ligands that are expressed in tumor, but not in
normal cells. The inhibition of NK cells is mediated by
the inhibitory killer-cell immunoglobulin-like receptors
or NKG2A/CD94 that recognize classical or non-
classical HLA class I molecules, respectively, which are
often lost or reduced in malignant cells [13, 14]. Con-
trarily to conventional chemotherapy, NK cells appear
to recognize and kill undifferentiated stem-like cells
[15, 16] by virtue of their ability to target non-dividing
cells and due to the low expression of MHC class I
molecules and possible up-regulation of stress-induced
activation ligands [17–19].
These findings, along with the relevance of CSCs in
BC progression and the inefficacy of current therapies,
prompted us to evaluate the therapeutic potential of
adoptive NK cell-based immunotherapy in the eradication
of competent CSCs and its impact on tumor progression,
an approach that is yet to be explored in BC.
Methods
Cell lines
Human BC (HT-1376 and UM-UC3) and the leukemic
(K562) cell lines (American Type Culture Collection,
Manassas, VA, USA) were cultured in RPMI 1640
medium (Gibco, Scotland, UK) supplemented with 10 %
heat inactivated fetal bovine serum (FBS), 200 mM of L-
glutamine (Sigma, St. Louis, USA), and penicillin
(100 IU/mL)-streptomycin (100 mg/mL) (Gibco,
Scotland, UK), at 37 °C in a 5 % CO2 incubator. CSCs were
isolated from the BC cell lines as described previously [5].
Isolation of NK cells from healthy donors and bladder
cancer patients
Polyclonal NK cells were isolated from healthy donor
(HD, n = 30, mean age: 45 years old) buffy coats pro-
vided by the Portuguese Blood and Transplantation In-
stitute or from the blood of BC patients after receiving
informed consent and approval by the Institutional Re-
view Board of Coimbra University Hospital (Approved
ID: 018-CE-2016). BC patients’ blood was collected from
a cohort of 10 male patients (mean age of 70 years) clas-
sified as Ta high-grade NMIBC before surgical treat-
ment. Peripheral blood mononuclear cells were
separated by density gradient centrifugation on Ficoll-
Hypaque (GE Healthcare, Uppsala, Sweden). NK cells
were subsequently isolated by negative selection using
the NK-cell isolation kit (Miltenyi Biotec) according to
the manufacturer’s instructions. Purified NK cells were
cultured in complete RPMI-1640 medium (106/mL) sup-
plemented with 10 % heat inactivated FBS, 200 mM of
L-glutamine (Sigma), penicillin (100 IU/mL), and
streptomycin (100 mg/mL). For activation and expan-
sion, NK cells were incubated with the interleukins IL-2
(250 IU/mL) and IL-15 (0.1 mg/mL) (Peprotech, Rocky
Hill, NJ, USA) for 24 and 48 h. The purity of the isolated
CD3−CD56+ NK cell populations was > 95 % in all
experiments.
Immunophenotyping of NK cells isolated from healthy
donors and bladder cancer patients
NK cells were stained with fluorochrome-conjugated
monoclonal antibodies against the following human
surface antigens: CD56-PE-Cy7, CD16-APC-H7, CD3/
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CD14/CD19-PerCP-CY5.5, CD94/CD27/CD62L-FITC,
NKG2C/NKp30/NKp46/NKG2D-APC, CD11b-PB, and
NKG2A/NKp44/NKp80-PE (all purchased from Biole-
gend, San Diego, CA, USA). For intracellular staining,
cells were washed, fixed, and permeabilized with Fix &
Perm cell fixation and permeabilization kit (Invitrogen,
Carlsbad, CA, USA) and stained with IL-4/TGF-β-FITC,
TNF-α-PE, IL-10-APC, and IFN-γ-PB. Appropriate iso-
type controls were used. A minimum of 100,000 events
were acquired using a FACSCanto II flow cytometer (BD
Biosciences, San Jose, CA, USA) and analyzed with the
FlowJo analysis software (Tree Star, Inc., Ashland, USA).
Results were expressed as the percentage of positively
stained cells in the NK cell gate.
Immunophenotyping of BC cells
Single-cell suspensions of parental and corresponding
sphere-forming cells were stained for 30 min at 4 °C
with fluorescent conjugated monoclonal antibodies
against HLA-ABC (clone w6/32, BioLegend), MICA/B
(clone 6D4, BioLegend), ULBP1 (clone 170818, R&D
Systems, Minneapolis, MN, USA), CD48 (clone 394607,
R&D Systems), Nectin-2/CD112 (clone 610603, R&D
Systems), CD155/PVR (clone 300907, R&D Systems),
and Fas/CD95 (clone 2R2, eBiosciences, San Jose, CA,
USA). For experiments with the supernatant of NK cells
(NK-SN), spheres were previously incubated for 4 h with
the supernatants of IL-2- and IL-15-activated NK cells
before phenotyping. Appropriate isotype-matched con-
trols were run with each experiment. Samples were ana-
lyzed using a FACSCanto II cytometer. A minimum of
100,000 events were collected and analyzed using the
FlowJo software.
CD107a degranulation and cytokine production
Freshly and IL-2/IL-15-activated NK cells (106 cells) col-
lected from HDs were co-cultured with target cells at an
effector-to-target (E:T) ratio of 3:1 in U-bottomed 96-well
plates for 4 h in a 5 % CO2 incubator with PE-conjugated
anti-CD107a (H4A3, BioLegend) and Brefeldin A
(Golgistop, BD). Stimulus with 25 ng/mL PMA plus
250 ng/mL ionomycin was used as a positive control
and NK cells alone were used as a negative control.
Cultured cells were then stained with fluorochrome-
conjugated monoclonal antibodies against human
blood surface antigens: CD3 PerCP/Cy5.5 (clone
HIT3a), CD14 PerCP/Cy5.5 (clone M5E2), CD19
PerCP/Cy5.5 (clone HIB19), CD16 FITC (clone 3G8),
and CD56 APC (clone HCD56), all purchased from
BioLegend. The percentage of CD3−CD56+ NK cells
positive for CD107a was calculated. All analyses were
performed in duplicate using BD FACSCanto II and
FlowJo analysis software.
Cytokines produced by 48 h IL-2/IL-15-activated NK
cells co-cultured with tumor cells at an E:T ratio of 10:1
were measured using ELISA kits according to the manu-
facturer’s instructions (granzyme B and IFN-γ: Abcam,
Cambridge, UK; and TNF-α: R&D Systems, MN, USA).
Chromium-51 (51Cr)-release assay
Target cells were loaded for 1 h with 50 μCi of 51Cr (Per-
kinElmer, Massachusetts), washed twice and incubated
with fresh or activated NK cells at different E:T ratios (1:1,
3:1 and 10:1) in 200 μL of complete RPMI in 96-well U-
bottom tissue culture plates at 37 °C in a 5 % CO2.
After a 4-h incubation period, the supernatants were
harvested and counted for released radioactivity in a
gamma counter (CRC-55tW Capintec), within a 51Cr
sensitivity energy window (300–400 keV). The specific
lysis of target cells was calculated as follows: Percentage
of specific lysis = (experimental release – spontaneous
release)/(maximum release – spontaneous release) × 100.
Spontaneous release was calculated from target cells
without effector cells. Maximum release was determined
by incubating target cells with 4 % SDS detergent. In all
experiments, the spontaneous release was < 20 % of
maximum release.
For NK cells blocking receptor experiments, activated
NK cells were pre-incubated with 10 μg/mL of anti-
NKG2D (clone 149810, R&D Systems), 10 μg/mL of
anti-DNAM-1 (clone 102511, R&D Systems), and
0.5 μg/mL of anti-FasL (clone ZB4, Merck Millipore,
Germany), individually or in combination, before co-
culture with tumor target cells.
NK cell supernatant assays
Both parental and CSCs were cultured for 4 h with the
supernatant harvested from 48-h IL-2/IL-15-activated
NK cells from HDs or BC patients. Thereafter, tumor
cells were assayed for aldehyde dehydrogenase (ALDH)
activity, expression of stemness-related markers and cell
surface ligands for NK receptors and chemosensitivity to
cisplatin.
Aldefluor assay
The activity of ALDH in tumor cells was measured using
the Aldefluor kit (Stem Cell Technologies, Vancouver,
BC, USA), according to the manufacturer’s instructions.
FACS was performed on a BD FACSCanto II flow cyt-
ometer. Data was analyzed with the FlowJo software.
Gene expression by real-time quantitative PCR analysis
(RT-qPCR)
Total RNA from sphere-forming and parental cells was
extracted using the ReliaPrep RNA Cell Miniprep System
(Promega) following the manufacturer’s instructions. The
quantity and quality of isolated RNA was measured by the
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ND-1000 spectrophotometer (NanoDrop Technologies).
Reverse transcription from 1 μg of total RNA was
performed using NZY First-Strand cDNA Synthesis kit
(Nzytech) and subsequent RT-qPCR for SOX2, ABCG2,
ABCB1, ALDH1A1, ALDH2, CD44, CD47, and KRT14
was performed as previously described [5]. Primers used
on RT-qPCR reaction are listed in Additional file 1: Table
S1. mRNA expression was normalized to three house-
keeping genes: 18S, GAPDH, and HRPT-1 using the ΔΔCt
method and Bio-Rad CFX Manager™ 3.0 software.
Chemosensitivity to cisplatin
Cells were treated with increasing concentrations of
cisplatin (Teva Pharma, Portugal) ranging from 1 to
100 μM over 48 h. Cell viability was analyzed using the
standard MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide] (Sigma) assay as previously
described [5]. Cell viability was expressed as the percent-
age of absorbance values of the treated cells related to
the untreated control wells considered as 100 %.
Bladder tumor specimens and immunohistochemistry
Bladder tumor samples were obtained from 25 patients
(19 males and 6 females) by transurethral resection at
Coimbra University Hospital, following appropriate
informed consent and ethical regulatory approval (Ap-
proved ID: 018-CE-2016). Tumors at initial diagnosis
were stratified into non-muscle-invasive low (n = 15) and
high (n = 7) grade and muscle-invasive tumors (n = 3) by
a pathologist, according to the 2004 WHO criteria [20].
Formalin-fixed paraffin-embedded tissue blocks were sec-
tioned at 3-μm thickness and incubated in a BenchMark
Ultra Ventana, with a primary antibody against CD56, a
surface marker for NK cells, clone 123C3 (1:50, Roche),
for 30 min at 37 °C, and reaction signal was developed
with 3-3′-diaminobenzidine tetrahydrochloride chromo-
gen. Standard procedures were used for visualization and
the intensity and percentage of positive staining was regis-
tered. Two investigators blinded to the data reviewed all
slides independently.
Animal studies
Animal studies were approved by the Organization
Responsible for Animal Welfare of the Faculty of
Medicine of Coimbra (Approved ID: ORBEA/91/2015/08)
and were performed according to National and Inter-
national guidelines on animal experimentation. Female
nude mice (Swiss nu/nu), 6–8 weeks old (Charles River
Laboratories, Barcelona, Spain) were housed under
pathogen-free conditions in individual ventilated cages.
The subcutaneous tumor model was induced by subcuta-
neous injection into the lower flank of 1 × 106 of Luc+
HT-1376 cells suspended in 100 μL of a 1:1 PBS/Matrigel
mixture. The orthotopic model that more closely
resembles the clinical and histopathological features of
primary MIBC was developed by intravesical instillation
of Luc+ HT-1376 cells as previously described [5].
Bioluminescent images were taken 24 h post-implantation
and every 3 days to monitor engraftment and growth of
tumor cells using an IVIS Lumina XR (Caliper Life-
Sciences, Hopkinton, MA, USA) after intraperitoneal injec-
tion with D-luciferin (150 mg/kg, Synchem, BHg, Germany)
with the animals under anesthesia (100 mg/kg ketamine and
2.5 % of chlorpromazine solution). Quantification of bio-
luminescent signals was performed using the living image
software version 4.10 (Xenogen). Values are expressed
as photons/sec/cm2/sr. Subcutaneous tumors started
the treatment on day 6 post-implantation by intratu-
moral inoculation of NK cells activated for 48 h (5 ×
106/50 μL) from HDs twice a week over 2 weeks.
Animals bearing subcutaneous or orthotopic tumors
were treated twice a week with healthy 48-h activated-
NK cells (5 × 106/mouse) via intratumoral and intravesi-
cal instillation, respectively, over 2 weeks. NK cells were
washed prior to administration and resuspended in PBS.
Tumor progression was monitored by bioluminescent
images 3 days after each treatment. Animals were sacri-
ficed after treatments or when presenting hematuria or
lost 20 % of initial body weight. Residual tumors were
excised and processed into paraffin blocks for immunohis-
tochemistry analysis of CD56 clone 123C3 (1:50, Roche)
and for two CSC-related markers, SOX-2 (clone D6D9,
1:100, Cell Signaling) and ALDH2 (clone EPR4493, 1:100,
Abcam) as described above for clinical samples.
Statistical analysis
Data are reported as the means ± SEM of the indicated
number of experiments. Statistical analysis and graphic
illustrations were performed using GraphPad Prism 6.0
software (San Diego, CA). Paired two-tailed Student’s
t-tests, ANOVA, and Tukey’s tests were used to calculate
P values. A P value of less than 0.05 was considered
significant.
Results
Activated-NK cells from healthy donors are highly
effective against chemoresistant bladder cancer stem-like
cells
The functional activity of NK cells from HDs against
parental cells and CSCs was evaluated by measuring
CD107a degranulation, release of cytokines, and lysis of
target cells following a 4 h co-culture period. Freshly iso-
lated NK cells were in the resting state in all E:T ratios
tested, as indicated by the low CD107a degranulation
rates, displaying weakly cytolytic activity against any cell
line including the MHC class I-negative K562 cells.
Upon stimulation with IL-2/IL-15, NK cells enhanced
their functionality and cytotoxicity against either parental
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cells or CSCs, as demonstrated by the enhanced CD107a
degranulation rates, and release of IFN-γ, TNF-α, and
granzyme B (a lytic granule) as compared to fresh NK cells
(Fig. 1a, b). During the 24 and 48 h of activation, the
percentage of viable NK cells decreased to 20–30 %.
The cytolytic activity of NK cells, measured by the
51Cr-release assay, increased with increasing E:T ratio
and reached a specific lysis greater than 70 % for an E:T
ratio of 10:1 in both cell subsets upon 48 h activation
with IL-2/IL-15 (Fig. 1c). No significant differences were
obtained between CSCs and parental cells, indicating
equal susceptibility of BC cells to activated NK cells
lysis.
Flow cytometry analysis of the various receptors in-
volved in NK cell effector functions showed a significant
up-regulation of the NCRs NKp44 (2.00 ± 1.16 % vs.
26.33 ± 3.84 %, P < 0.01) and NKp30 (0.12 ± 0.02 % vs.
2.68 ± 0.33 %, P < 0.01), and of the NKG2D (65.00 ±
Fig. 1 Allogeneic activated-NK cells are effective against bladder cancer stem and non-stem cells. a Representative FACS dot-plots of CD107a
release in resting and 24- or 48-h IL-2/IL-15-activated CD3−CD56+ NK cells after 4 h co-culture with spheres and corresponding parental cells at
a 3:1 effector-to-target (E:T) ratio. The graph shows the percentage of CD3−CD56+CD107a+ expressing cells. PMA/ionomycin was used as the positive
control and NK cells alone as the negative control. b Release of IFN-γ, TNF-α, and granzyme B by 48-h activated NK cells after 4 h co-culture with
parental or spheres at an E:T ratio of 10:1, determined by ELISA. Graphs represent the means ± SEM, n = 4. c Percentage of dead target cells measured
by the 51Cr-release assay after 4 h co-culture with resting and IL-2/IL-15-activated NK cells at different E:T ratios. K562 cells were used as a positive
control. Graphs show the mean ± SEM, n = 5
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9.45 % vs. 96.33 ± 1.76 %) and DNAM-1 (78.67 ± 3.66 %
vs. 92.25 ± 1.65 %) activating receptors upon 48 h activa-
tion, relative to resting NK cells (Additional file 2: Figure S1),
indicating the crucial role of stimulatory cytokines in
NK cell antitumor properties.
Moreover, the distribution of gated CD56+CD3− NK
cells with regard to CD16 expression changed upon
stimulation with IL-2/IL-15, resulting in a significant
increase in the CD16− subpopulation in relation to
resting NK cells. The median percentage of
CD56brightCD16−, which in freshly NK cells was of
2.68 ± 0.20 % (2.34–3.29 %), increased to 4.32 ± 0.21 %
(3.98–4.85 %) and to 8.57 ± 1.02 % (6.64–10.10 %)
upon 24- and 48-h cytokine activation, respectively.
No significant changes were observed in the percent-
age of CD56dimCD16+ cells.
Bladder CSCs display increased expression of ligands
recognized by NK cell activating receptors
To evaluate the ability of BC cells to stimulate NK-
mediated cytotoxicity, both parental cells and CSCs were
characterized regarding the expression of ligands that
engage activating and inhibitory NK receptors. Both
parental cells and CSCs expressed activating ligands in-
volved in NK recognition, namely MICA/B and ULBP-1
ligands for NKG2D-activating receptor and PVR and
Nectin-2 for DNAM-1, as well as the Fas death receptor
(Fig. 2a). Interestingly, all activating ligands were found
Fig. 2 Bladder cancer cells express multiple ligands for NK-cell activating receptors. a Representative histograms illustrating the expression of
HLA-ABC, CD112, CD155, MICA/B, ULBP-1, and Fas in parental cells (black solid lines) and spheres (black dotted lines). Gray profiles represent
isotype-matched controls. The graph represents the mean percentage of each ligand in both cell subsets of three independent experiments.
b Percent killing of target cells after 4 h co-culture with NK cells activated for 48 h in the presence of blocking antibodies against NKG2D,
DNAM-1, and FasL, separately and in combination. Bar graph represents the mean + SEM (n = 4). *P < 0.05, **P < 0.01, and ***P < 0.001 compared to
untreated NK cells
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more highly expressed in the CSC subsets in comparison
to corresponding parental cells. The HLA-class I mole-
cules (HLA-ABC), which play a major role in NK cell
inhibition, were expressed in both BC cell lines and
slightly decreased in spheres.
NKG2D and DNAM-1 activating receptors mediate bladder
CSC lysis
To identify the contribution of the different activating
receptors behind NK cell recognition of target cells, we
performed blocking studies using specific monoclonal
antibodies. As indicated by the killing assay (Fig. 2b),
blocking NKG2D (P < 0.05) and DNAM-1 (P < 0.01) re-
ceptors impaired the overall cytolytic activity of NK cells
against both BC cell subsets. Additionally, Fas-L block-
ing decreased the ability of NK cells to kill the stem-like
fraction of the UM-UC3 cell line in agreement with the
high surface expression levels of Fas in these cells. The
combined mAb-mediated blocking of NKG2D, DNAM-
1, and Fas-L receptors almost completely abrogated NK
cell-mediated killing of spheres from the two BC cell
lines, in agreement with the higher density of ligands
interacting with these specific NK-activating receptors.
Supernatants from NK cells induce differentiation and
sensitize CSCs to cisplatin
In addition to increased chemoresistance, CSCs are
characterized by their ability to self-renew and differenti-
ate. We tested whether NK cells could induce CSCs
towards a more differentiated phenotype rendering them
susceptible to chemotherapy.
Therefore, spheres were incubated with the superna-
tants of activated-NK cells for 4 h, followed by analysis
of stemness related markers previously identified [5].
The ALDH activity, considered a functional readout of
stemness, decreased by 60 % in spheres after 4 h incuba-
tion with NK supernatants (Fig. 3a). Accordingly, the
transcript levels of two ALDH isoforms responsible for
ALDH activity (ALDH1A1 and ALDH2) were also down
regulated in both CSC populations (Fig. 3b). The mRNA
expression levels of other stem cell-related markers,
including pluripotency factors (SOX2, POU5F1, and
NANOG), urothelial basal cell-specific markers (CD44,
CD47, and KRT14), and drug resistance-related trans-
porters (ABCG2 and ABCB1), were also significantly
downregulated in HT-1376 spheres. A similar trend, al-
though not significant, was noticed in UM-UC3 spheres.
No significant transcription changes were observed in
corresponding parental cells (data not shown). Addition-
ally, pre-treatment with the NK cell supernatant sensi-
tized CSCs towards cisplatin, a drug currently used in
the treatment of MIBC, as compared to non-pretreated
cells (Fig. 3c).
NK cells from bladder cancer patients display low
expression of NCRs and fail to mediate CSCs lysis
Next, we analyzed the phenotypic status and functional-
ity of NK cells collected from the peripheral blood of
high-grade NMIBC patients with high risk of recurrence.
NK cells displayed decreased responsiveness to cytokine
stimulation, as indicated by the overall lower specific
lysis observed in both cell subsets comparatively to
activated-NK cells from HDs (Fig. 4a, b), with consider-
ably reduced cytotoxicity against spheres (P < 0.01), con-
trary to healthy NK cells, which displayed an equal
capacity to kill stem and parental cells (Table 1). Pheno-
typic analysis showed a reduced expression of NKp30,
NKp44, and the co-receptor NKp80 in patient NK cells,
as compared with HDs (Fig. 4c). The expression of the
adhesion molecule CD62L and the terminal differenti-
ation marker CD57 was significantly decreased in NK
cells from BC patients. Furthermore, NK cells from pa-
tients showed up-regulation of the immunosuppressive
anti-inflammatory cytokines TGF-β, IL-4, and IL-10, and
down regulation of pro-inflammatory cytokines TNF-α
and IFN-γ, in agreement with the impaired NK cell
activity (Table 1).
Moreover, exposure of CSCs to NK supernatants de-
rived from BC patient cells did not decrease the expres-
sion of stemness-related markers in spheres. Rather, a
trend was observed towards up-regulation of the major-
ity of analyzed genes, suggesting that NK cells release
factors that maintain or exacerbate the stemness features
of tumor cells (Fig. 4d).
To further evaluate whether tumor-infiltrating NK
cells might indeed represent an ongoing anti-immunity
response in BC, we analyzed the expression of CD56+
NK cells in a panel of human BC samples classified as
low- and high-grade NMIBC and MIBC at diagnosis.
Our results revealed a small percentage of infiltrating
CD56+NK cells within tumors in all tumor stages, indi-
cating these tumors are not infiltrated by NK cells, being
unlikely to greatly contribute to the elimination of tumor
cells (Fig. 4e).
Adoptive transfer of healthy activated-NK cells display
anti-tumor activity in bladder cancer xenografted models
Given the considerable low cytotoxic activity of NK cells
from BC patients, we focused on the anti-tumoral activ-
ity of NK cells from HD in animal models induced by
xenotransplantation of HT-1376 cells. The HT-1376 cell
line contains a subpopulation of CSCs, as previously
demonstrated by the presence of an ALDH+ population
with sphere-forming ability, and forms an orthotopic
heterogeneous tumor resembling the clinical condition
of MIBC comprising stem-like and proliferative differen-
tiated cell populations, as previously demonstrated by
our group [5].
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First, we evaluated the antitumor activity of NK cells
in mice bearing localized subcutaneous tumors. The
treatment started 6 days after cell inoculation and was
performed twice a week by intratumoral injection of 5 × 106
activated-NK cells. An immediate and progressive decrease
in the tumor size was observed, being totally abolished after
the fourth administration (Fig. 5a). At that time, the treat-
ment was finished and the animals were monitored for up
to 2 weeks, and no tumor relapse was observed. Thereafter,
we tested the same approach, but in an organ-specific
microenvironment using an orthotopic model (Fig. 5b). NK
cells were instilled intravesically into the bladder lumen
4 weeks after tumor cells implantation. The treatment re-
sulted in a progressive decrease of tumor burden by 80 %
after the fourth inoculation with total remission in one of
the five animals treated.
The immunostaining of residual tumors showed a high
degree of CD56+ tumor-infiltrating NK cells, and a
marked reduction of two stemness markers (SOX-2/
ALDH2) expression in treated tumors, compared to
Fig. 3 NK cell-derived supernatant (SN) promotes the differentiation of cancer stem-like cells and increases their sensitivity to cisplatin. a Representative
flow cytometry analysis of ALDH enzymatic activity in spheres after 4 h with NK-derived SN. The ALDH inhibitor DEAB was used as a negative control
to establish the baseline fluorescence of the cells. Bar graph shows the percentage of ALDH+ cells (mean ± SEM, n = 3). b Fold-change mRNA
expression levels of stemness-related markers in spheres treated with NK-SN relative to untreated spheres set as 1 (mean ± SEM, n = 5).
c Cytotoxic effects of cisplatin in spheres cultured in DMEM/F12 (black bars) and upon culture with NK-SN (gray bars) for 4 h determined
by the MTT assay. The percentage of viable cells was normalized respective to untreated cells (mean ± SEM, n = 3). d Representative histograms
illustrating the expression of specific ligands on the surface of spheres cultured in DMEM/F12 medium (gray histograms) or previously incubated with
NK-SN for 4 h (black histograms). *P < 0.05, **P < 0.01, and ***P < 0.001 represents spheres in NK-SN vs. spheres in regular DMEM/F12
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untreated controls (Fig. 5c), confirming the CSC-
targeting ability of locally administered NK cells in an
organ-specific microenvironment.
Discussion
A major challenge in BC treatment is the risk of pro-
gression to muscle-invasive forms or metastatic disease,
a process that appears to be strongly related to the
presence of CSCs that are resilient to current conven-
tional therapies. We provided evidence that both stem
and non-stem cells can be recognized and effectively
killed by ex vivo-activated allogeneic NK cells from HDs,
but not from BC patients.
Compared with resting cells, cytokine-activated NK
cells displayed an increased density of major activating
receptors, crucial for NK cell cytokine production and
Fig. 4 NK cells from bladder cancer (BC) patients have impaired cytolytic activity and are ineffective against cancer stem-like cells. a Cytolytic
activity of resting and IL-2/IL-15-activated NK cells after 48 h of activation derived from BC patients against BC parental cells and spheres after 4 h
co-culture at a 10:1 ratio measured by the 51Cr release assay. b Comparative analysis of lytic activity of NK cells derived from HDs and BC patients
against spheres and parental cells. c Flow cytometry analysis of the natural cytotoxicity receptors, adhesion molecule CD62L, differentiation marker
CD57, and the cytokine profile of BC patient (gray boxes, n = 10) and HD (white boxes, n = 8) NK cells. Graphs represent the percentage of positive cells
(mean ± SEM). *P< 0.05, **P< 0.01, and ***P< 0.001 HD versus BC patients. d Fold-change mRNA expression levels of stemness-related markers in spheres
treated with NK-SN from BC patients relative to untreated spheres set as 1 (mean ± SEM, n = 5, *P< 0.0 5 and **P< 0.01). e Immunohistochemical staining
for CD56 in serial sections of tumoral tissue from BC patients with non-muscle-invasive, low grade; non-muscle-invasive, high grade; and muscle-invasive
tumors. Original magnification: ×400
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cytotoxicity. Moreover, the expansion of CD56brightCD16−
NK cells is likely to contribute to the enhanced NK
cell-mediated cytotoxicity. Although the lytic activity
of NK cells is generally attributed to the CD56dim
subset, it is conceivable that the CD56bright subset
becomes more mature and equally cytotoxic as the
CD56dim subset following cytokine stimulation. In line
with this, Romee et al. [21] showed that IL-15 primed
CD56bright NK cells with a highly potent antitumor
activity in acute myeloid leukemia.
The phenotypic analysis of BC cells confirmed the
high expression levels of several ligands recognized by
NK activating receptors in both tumor cell subsets,
making them suitable targets for NK cell-based immuno-
therapy. The levels of HLA class I molecules were not
enough to protect tumor cells from NK-mediated lysis,
suggesting that the susceptibility of BC cells might not en-
tirely depend on missing self-recognition and that NK cell
activation induced by activating ligands is a strong mech-
anism to overcome MHC class I inhibitory signals. This is
consistent with a previous report showing that the loss of
MHC inhibitory signals did not change the pattern of NK
cell degranulation towards BC cells [22].
The decreased lytic activity observed in receptor
blocking experiments confirmed the importance and co-
operation pattern of DNAM-1- and NKG2D-dependent
mechanisms in trigger activation signals and in overcoming
the inhibitory signals resulting from MHC-I recognition, in
both cell subsets. We cannot exclude that this alloreactivity
of NK cells against tumor cells might also be caused by a
killer-cell immunoglobulin-like receptor/HLA receptor-
ligand mismatch, an aspect that was not explored in this
work and deserves investigation.
Importantly, NK cells release critical factors that regu-
late the switch of spheres into a more differentiated status,
thus reversing their resistance to cisplatin and indicating a
dual effect on depletion of the CSC pool by direct killing
and by generation of differentiated cells vulnerable to con-
ventional therapies. This inducing-differentiation effect,
already described and referred to as split energy, has been
attributed to anergized NK cells that lose cytotoxicity but
augmented the secretion of cytokine (IFN-γ, TNF-α) in-
ducers of CSC differentiation [19, 23].
NK cells from BC patients are less responsive to cyto-
kine activation and display a reduced lytic activity, espe-
cially against CSCs, due to the low expression of NCRs
and CD62L, crucial for recognition and killing of target
cells, and by the presence of immature CD57− NK cells.
Apart from the modified NK phenotype, the increased
levels of immunosuppressive cytokines (TGF-β, IL-10,
and IL-4) and reduced expression of IFN-γ/TNF-α pre-
vented an effective antitumor immune response and
abolished their differentiation-inducing effects on CSCs
[24, 25]. Finally, factors released by NK cells from BC
patients were ineffective in driving differentiation of
CSCs, which may contribute to the expansion of the
CSC pool and subsequent tumor progression.
Recent studies suggest that malignant cells can bypass
NK surveillance by releasing soluble forms of the
NKG2D ligands, suppressing NK cell-mediated cytotox-
icity. Marked levels of the soluble form of the MHC
class I-related chain A, identified as a human NKG2D
ligand, were found in the sera of patients with dissemi-
nated head-and-neck squamous cell [26] and human
hepatocellular carcinomas [27] and neuroblastoma [28].
This tumor-derived soluble inhibitory ligand appears to
be responsible for the downregulation of NKG2D ex-
pression in NK cells and subsequent impaired NKG2D-
mediated cytotoxicity in patients with advanced disease.
This mechanism also impairs the adaptive immunity due
to the loss of allostimulatory capacity of dendritic cells
mediated by NK cells [27]. Moreover, the downregula-
tion of NKG2D was also reported in infiltrating and
matched peripheral blood T cells in cancer patients with
circulating tumor-derived soluble MHC class I-related
chain A, suggesting this ligand can induce an impair-
ment of the responsiveness of tumor antigen-specific
effector T cells, leading to tumor escape from immu-
nosurveillance [29]. The existence and nature of this
immunosuppressive mechanism should be further
explored in BC patients.
Table 1 Profile of NK cells derived from healthy donors and
bladder cancer patients
Healthy donors Bladder cancer patients
51Cr-release assay
HT-1376 80.12 ± 4.14 % 38.67 ± 8.88 %***
HT-1376 spheres 75.44 ± 6.53 % 11.74 ± 3.12 %***
UM-UC3 73.69 ± 5.40 % 41.38 ± 10.71 %**
UM-UC3 spheres 67.52 ± 7.61 % 18.19 ± 4.17 %***
NCRs
NKp30 54.68 ± 4.98 % 33.55 ± 5.09 %*
NKp44 26.35 ± 9.18 % 0.52 ± 0.20 %***
NKp46 42.93 ± 3.70 % 49.09 ± 6.09 %
NKp80 98.34 ± 0.32 % 91.36 ± 2.20 %**
CD62L 33.40 ± 1.44 % 24.30 ± 2.57 %*
CD57 31.08 ± 2.54 % 20.86 ± 2.14 %**
Cytokines
TNF-α 0.36 ± 0.13 % 0.23 ± 0.08 %
IFN-γ 0.23 ± 0.06 % 0.08 ± 0.03 %
TGF-β 0.14 ± 0.02 % 0.32 ± 0.15 %
IL-4 0.007 ± 0.003 % 0.42 ± 0.24 %
IL-10 0.81 ± 0.19 % 3.36 ± 1.62 %
51Cr chromium-51, NCRs natural cytotoxic receptors
*P < 0.05; **P < 0.01; ***P < 0.001 healthy donors (n = 8) vs. bladder cancer
patients (n = 10)
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These findings highlight the role of the tumor micro-
environment in host immune response impairment and
NK lytic function, and may explain the poor efficacy of
adoptive transfer of autologous NK cells frequently ob-
served in cancer patients with melanoma, lymphoma,
and breast cancer due to NK-cell dysfunction [30–32].
Immunohistochemical analysis of CD56+ infiltrating-NK
cells in biopsy specimens of BC patients revealed a poor
tumor infiltration, independently of tumor stage and
grade, reflecting an inefficient homing of NK cells in BC,
unlikely to control tumor progression. Similar results
were reported by Kripna et al. [33] in BC samples, sug-
gesting tumor-infiltrating NK cells are not a prognostic
factor in BC, contrarily to other tumor types.
The in vivo studies showed a remarkable anti-tumor
activity of healthy activated-NK cells in BC xenografted
Fig. 5 Allogeneic activated-NK cells from healthy donors are effective in eradicating cancer stem-like cells in bladder cancer mouse models.
a Serial bioluminescent images of a representative subcutaneous tumor-bearing mouse after intratumoral injection of activated-NK cells. b Anti-tumoral
effects of activated-NK cells administered intravesically in mice bearing an orthotopic bladder cancer. All animals were treated twice a week with 5 × 106
NK cells for 2 weeks and were monitored each 3 days after treatment. The tumor size was evaluated by quantification of the bioluminescent signal
(photons/sec/cm2/sr) in a region of interest drawn around the tumor. The graphs represent tumor progression of untreated and treated
animals normalized to the bioluminescent signal at the beginning of the treatment (n = 5, per group). c Immunohistochemical staining
for CD56, ALDH2 and SOX2 in serial sections of an orthotopic untreated tumor (upper row) and in a residual treated tumor after the
fourth intravesical administration of activated-NK cells (lower row). Original magnification: ×400
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models. The intratumoral delivery of activated-NK cells
leads to a complete abolishment of subcutaneous tumors
with no evidence of recurrence, likely reflecting the abil-
ity of NK cells to kill CSCs and non-CSCs. In the ortho-
topic model, the intravesical administration of NK cells
resulted in a massive decrease in the tumor burden,
clearly demonstrating the intrinsic killing ability of NK
cells in the tumor microenvironment. The considerable
decreased expression of stemness markers in residual tu-
mors confirm the CSC-targeting ability of NK cells, in
addition to the elimination of differentiated tumor cells.
We argue that this tremendous antitumor efficacy is
largely related to the extensive tumor infiltration of NK
cells, achieved via direct intravesical administration, sur-
passing the poor infiltration when delivered intraven-
ously (data not shown). This has been observed in
animal models and clinical studies, and is considered a
critical factor for efficacious adoptive NK cell therapy
when delivered systemically [34–36]. The innate ability
of NK cells to target both stem and non-stem cell popu-
lation by NK cells is of utmost importance to achieve a
meaningful disease remission and survival benefits since
non-stem cells might switch to a stem-like phenotype
able to sustain tumor growth.
A limiting factor of this study is the use of immuno-
compromised mice lacking T cells that play a central
role in tumor surveillance [37, 38]. It is well-known that
NK cells, through release of cytokines, exchange bidirec-
tional activating signals in a positive feedback with den-
dritic and CD4+ T cells, with consequent enhancement
of an antitumor immune response [37, 38]. The lack of
this synergistic effect with other immune effectors, only
possible in an immunocompetent host, is likely to
underestimate the anti-tumor response we have ob-
served in our model, which was nevertheless notably sig-
nificant. However, future studies using humanized
mouse models to reproduce the complex interactions of
NK cells with other cells of the immune system are
needed to more accurately predict the anti-tumor clin-
ical efficacy of allogeneic NK cell-based immunotherapy.
Conclusions
We demonstrated, for the first time, that intravesical
therapy with ex vivo-activated allogeneic NK cells provides
a rapid and noteworthy anti-tumoral response against BC
by targeting both stem and non-stem cell populations. Im-
portantly, the ability of NK cells to drive CSC differenti-
ation, viewed as major precursors of muscle-invasive
forms, are likely to prevent or delay recurrence and/or
disease progression. These findings, although preclinical,
provide evidence for the high therapeutic potential of NK
cell-based adoptive immunotherapy in the eradication of
bladder CSCs, an approach that should be exploited as
part of a combinatorial therapeutic strategy in BC.
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